AML

(redirected from acute myelogenous leukemia)
Also found in: Dictionary, Thesaurus, Medical, Acronyms, Encyclopedia.

Adjustable Rate Mortgage

A mortgage with an interest rate that changes periodically. Generally speaking, an adjustable rate mortgage is linked to some major benchmark rate; for example, the interest rate may be stated as "LIBOR + 1%." The mortgage may or may not have a cap on how much the interest rate can rise or fall, or on how often the interest rate may change. Very often, the initial interest rate for an adjustable-rate mortgage is lower than that for a fixed-rate mortgage. This allows more people to qualify for an adjustable-rate mortgage; however, this kind of mortgage can be risky because the interest rate (and therefore the monthly payment) can rise unexpectedly. Indeed the prevalence of ARMs has been blamed for the housing bubble in the mid-2000s and the subsequent recession. See also: Credit Crunch, Teaser Rate.

Anti-Money Laundering

Any law or regulation requiring an institution to perform due diligence on potential clients to ensure that it is not aiding in a money laundering scheme. If the institution does not conduct due diligence properly, it may be held legally liable for the money laundering activities. These regulations were an important part of the USA PATRIOT Act.

AML

See adjustable mortgage loan.
References in periodicals archive ?
Leading organisations in Acute Myelogenous Leukemia research include:
Life Science Analytics, Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Therapy Area Pipeline Report contains detailed information on the acute lymphoblastic leukemia or leukemia or chronic lymphocytic leukemia or chronic myelogenous leukemia or acute myelogenous leukemia or hairy cell leukemia drug pipeline.
First, this progenitor cell is also thought to be the cell that, after a number of mutations, eventually becomes the acute myelogenous leukemia stem cell.
com/reports/c68778) has announced the addition of "Acute Lymphoblastic Leukemia or Leukemia or Chronic Lymphocytic Leukemia or Chronic Myelogenous Leukemia or Acute Myelogenous Leukemia or Hairy Cell Leukemia Drug Pipeline Report" to their offering.
The 13-year-old son of longtime UPI driver John Ito was recently disnosed as having Acute Myelogenous Leukemia.
The company has four drug programs in clinical development: Tamibarotene, INNO-406, INNO-206, and INNO-305, for the treatment of acute promyelocytic leukemia, chronic myelogenous leukemia, small cell lung cancer, and acute myelogenous leukemia respectively.
5) In this 1990 file photo, Anissa holds the newborn Marissa, who was conceived by her parents in hopes she could provide bone marrow for her older sister, who was dying of acute myelogenous leukemia.
Eleos' lead drug, cenersen (EL625), is currently in a Phase II trial in acute myelogenous leukemia (AML).
A Food and Drug Administration advisory committee voted unanimously Friday to recommend that the agency approve the drug for use in patients being treated for Acute Myelogenous Leukemia.
In addition to the recently acquired Tamibarotene for acute promyelocytic leukemia, the company has three drug programs in clinical development, INNO-406, INNO-206, and INNO-305, for the treatment of chronic myelogenous leukemia, small cell lung cancer, and acute myelogenous leukemia respectively.
The Phase 1 trial enrolled 17 patients with myelodysplastic syndromes (MDS), refractory acute myelogenous leukemia (AML) or CLL.
Full browser ?